Find Academic Supervisors

Dr. Sabine Hoja works as a Researcher at the Department of Sport Science within the Faculty of Human Sciences at the University of Regensburg. She holds a PhD in Physiology (2011-2016, University of Regensburg) and a Diplom in Molecular Medicine (2006-2011, FAU Erlangen-Nuremberg). Her career spans academic positions in sport science (since 2017) and previous research roles in neuropathology and pathology departments (2011-2016). Research Focus : Mindfulness in Sports Sustainable Behavior in Athletes Positive Psychology Applications Molecular Biology of Gliomas (earlier work) Teaching : Bachelor: Introduction to Sport Psychology, Motor Skills & Cognition, Exercise in Internal Medicine/Oncology, Athletics Master: Psychological Disorders in Competitive & Recreational Sports, Mindfulness in Sports, Scientific Study Conduct Teacher Training: Motor Skills & Cognition, Athletics Scientific Contributions include 11 peer-reviewed publications (2016-2024) across neuroscience, sport psychology, and sustainability research. Her work explores the intersection of mindfulness, psychological traits, and environmentally conscious behavior in athletic contexts. Contact : sabine.hoja@ur.de | Office: Building Sportzentrum, Room 40.11

• Sport Psychology
• Mindfulness in Sports
• Sustainable Behavior in Athletes
• +3 more

Prof. Dr. Matthias Dobbelstein is Professor of Molecular Oncology and Head of the Department of Molecular Oncology at the Georg-August-Universität Göttingen since 2005. His research examines cancer cell responses to chemotherapy, focusing on DNA replication stress, p53 signaling, and non-genotoxic drug candidates. The lab studies molecular mechanisms of colorectal cancer therapy response using siRNA screening, fluorescence microscopy, and DNA replication analysis. Current work evaluates histone deacetylase and heat shock protein inhibitors alongside traditional chemotherapeutics.

• Cancer Chemotherapy
• DNA Damage Response
• Tumor Suppressor p53
• +1 more

Dr. Silvia Belluti is an Assistant Professor in the Department of Life Sciences at the University of Modena and Reggio Emilia since September 2022. Her research focuses on molecular mechanisms in cancer progression and epigenetic regulation, particularly in prostate cancer and melanoma. Her work spans several subfields including: HDAC and Hsp90 inhibition strategies Transcription factor NF-Y in cancer aggressiveness Epitranscriptomic regulation of gene expression Metal-based pharmacological agents Alternative splicing in tumor development Recent publications highlight her expertise in developing dual inhibitors (e.g., Hsp90/HDAC6), exploring sigma-2 receptor antagonists for melanoma, and investigating epigenetic mechanisms in skeletal muscle regulation. She collaborates with researchers like Carol Imbriano and Giulio Rastelli on computational and experimental approaches to cancer therapy.

• Molecular Biology
• Cancer Research
• Gene Expression Regulation
• +7 more

Prof. Dr. Björn Burckhardt serves as Professor at the Institute for Pharmaceutical and Medicinal Chemistry at the University of Münster, where he leads research in Clinical Pharmacy with a focus on Individualized Pharmacotherapy. His laboratory, located in Room 120.268 at Corrensstr. 48, Münster, conducts cutting-edge research on pathophysiologically relevant peptide cascades using mass spectrometry. Dr. Burckhardt's research primarily centers on the kallikrein-kinin system and its complex interplay with the renin-angiotensin-aldosterone system, complement system, and neurokinins. His work has significant implications for understanding and treating major diseases including hypertension, diabetes mellitus, cancer, hereditary angioedema, sepsis, and malaria. By developing reliable mass spectrometric techniques, his team aims to identify new drug targets and advance personalized medicine approaches through comprehensive pharmacokinetic, pharmacodynamic, and metabolomic analyses. His recent publications demonstrate a strong focus on antimalarial compounds, HDAC inhibitors for cancer therapy, and the role of peptide systems in inflammatory conditions including COVID-19. The research spans from analytical method development to clinical applications, with particular emphasis on pediatric pharmacology and translational medicine. Dr. Burckhardt has earned significant recognition including: Frey-Werle Prize (2022) for contributions to kallikrein-kinin system research Marie Skłodowska-Curie Global Fellowship (2022) He actively collaborates through consortia including LENA and CARS, with research that bridges analytical chemistry, pharmacology, and clinical medicine. His laboratory regularly recruits PhD students with backgrounds in pharmacy, chemistry, and related disciplines for research involving mass spectrometry and bioanalytical techniques. The research group comprises multiple scientists including Dr. Tanja Gangnus (who received the Walter Schunack Prize in 2023), several research assistants, and technical staff, working together to advance understanding of peptide cascades and their clinical applications.

• Individualized Pharmacotherapy
• Clinical Pharmacy
• Mass Spectrometry
• +7 more

Daniel Wegener is a researcher at the University Clinic for Radiation Oncology within the School of Medicine at the University of Tübingen . His work spans multiple disciplines, including radiation oncology, cancer biology, and social psychology. Research interests include: Radiation oncology for urogenital tumors Inhibition of RAS activation via SOS1 targeting Public health guidelines for tuberculosis prevention Psychological replication frameworks and attitude change theories Development of histone deacetylase inhibitor assays for drug screening Notable publication trends: 2024 : Contributed to tuberculosis isolation guidelines 2023 : Lifestyle interventions in maternal health 2022 : Chemical synthesis of stable tellurium compounds 2021 : MR-linear accelerator applications in prostate cancer 2020 : Validity-based replication in psychology 2003 : Histone deacetylase inhibitor screening 1997 : Foundational work on attitude change models His contributions also extend to computational neuroscience and statistical methodology, with collaborations across diverse fields.

• Radiation Oncology
• Cancer Research
• Histone Deacetylase Inhibitors
• +6 more

Hany Ibrahim is an Associate Professor at the Institute of Pharmacy, Martin-Luther-Universität Halle-Wittenberg, within the Faculty of Natural Sciences I - Biosciences. He is a member of the Medicinal Chemistry group, focusing on the development of small molecule inhibitors and PROTACs targeting histone-modifying enzymes, particularly HDACs. His research lies at the intersection of chemical biology and drug discovery, with applications in oncology, neurodegenerative disorders, and infectious diseases. Funded by the prestigious Alexander von Humboldt Foundation, his work aims to design isoform-selective HDAC inhibitors and develop novel PROTACs for targeted degradation of HDAC class I isoforms (HDAC 1, 2, 3, 8). His research interests include: Targeted protein degradation via ubiquitin-proteasome system Epigenetic regulation through HDAC modulation Hybrid heterobifunctional molecules (PROTACs) Chromatin structure and gene expression control The research has broad implications for treating diseases such as cancer, Alzheimer’s disease, and latent HIV infection. Scientific Support and Recognition: Alexander von Humboldt Foundation Funding Professional Profiles: His scholarly output can be explored via Google Scholar , Publons , and ResearchGate . Research Team and Affiliation: He conducts his research within the Medicinal Chemistry group under the Department of Pharmaceutical Chemistry and Clinical Pharmacy, contributing to the university’s strong presence in pharmaceutical sciences and chemical biology.

• Medicinal Chemistry
• Targeted Protein Degradation
• Epigenetics
• +7 more

Prof. Dr. Martin Göttlicher is the Director of the Institute of Molecular Toxicology and Pharmacology at Helmholtz Munich and holds a joint appointment with Technical University Munich as Chair of Toxicology and Environmental Hygiene. His research bridges molecular mechanisms of chemical interactions with human physiology, focusing on therapeutic and toxicological implications. Education: Basic medical training, postdoctoral fellowship at Karolinska Institute (1991-1994), habilitation fellowship by DFG (1994-2002). His work explores how chemicals influence gene regulation and cellular processes, including the discovery of valproic acid as a histone deacetylase (HDAC) inhibitor and PPARα activation by fatty acids. This research spans epigenetics, metabolic disorders, and cancer therapy. Recent publications highlight his contributions to HDAC inhibition in cancer and cardiac physiology, dioxin receptor mechanisms, and drug repurposing for leukemia. Key trends involve epigenetic regulation, metabolic signaling, and translational toxicology. Scientific Awards: German Cancer Award (2006) DFG Habilitation Fellowship (1994-1996) EMBO Long-term Fellowship (1991-1992) Göttlicher leads drug discovery initiatives at Helmholtz Munich, chairs professional education commissions for toxicologists, and contributes to cancer and metabolic disease research through molecular and cellular approaches.

• Molecular Toxicology
• Pharmacology
• Gene Regulation
• +4 more

Prof. Dr. Christian Johannes is a faculty member in the Faculty of Biology at the University of Duisburg-Essen, where he leads research in the Molecular Genetics I group at the Center of Medical Biotechnology (ZMB). His work is deeply rooted in molecular and cellular genetics, with a strong emphasis on DNA integrity and genomic stability. His research focuses on the mechanisms of chromosomal aberrations, DNA double-strand breaks, and the biological effects of radiation and nanomaterials. He has extensively studied the genotoxic potential of restriction endonucleases and ionizing radiation, contributing significantly to the fields of radiobiology and genetic toxicology. His more recent work includes investigations into epigenetic regulation in cancer and the cytogenetic impacts of silver nanoparticles. The analysis of his recent publications reveals a consistent trajectory in understanding genomic instability, with evolving methodologies from classical cytogenetics to advanced multi-center nanotoxicology studies. His work bridges fundamental molecular biology with applied medical biotechnology, particularly in cancer and environmental health contexts. Among his scientific contributions are numerous peer-reviewed articles in high-impact journals such as Mutation Research , Radiation Research , and BMC Cancer . While specific awards are not mentioned in the text, his sustained publication record over decades reflects recognition in the scientific community. Prof. Johannes has been actively involved in advising and collaborative research, particularly with Prof. Günter Obe and other international teams. His work has been supported by various grants, though specific funding sources are not detailed here. He has contributed to both experimental design and data interpretation across a wide range of genotoxicity assays. He conducts his research within the Molecular Genetics I laboratory at the Center of Medical Biotechnology, a multidisciplinary environment fostering innovation in medical genetics and biotechnological applications. His team likely includes researchers and students focused on molecular mechanisms of DNA damage and repair.

• Molecular Genetics
• Genotoxicology
• Radiation Biology
• +7 more

Prof. Dr. Siavosh Mahboobi is a faculty member at the University of Regensburg , affiliated with the Institute of Pharmacy and working in the Pharmaceutical/Medicinal Chemistry I department. His research focuses on molecular mechanisms of cancer and the development of targeted therapies. Signal transduction pathways in cancer FLT3 and PDGFR tyrosine kinase inhibitors HDAC and tubulin inhibition strategies EGFR-targeted therapies 5-HT receptor agonists/antagonists His work emphasizes the design of small molecules that disrupt cancer-related signaling. He has received the PHOENIX Pharmaceutical Sciences Award (2011) for his contributions to anticancer drug development.

• Signal Transduction in Cancer
• Tyrosine Kinase Inhibitors
• HDAC Inhibitors
• +3 more

Manfred Jung is Professor and Chair of Pharmaceutical and Medicinal Chemistry at the University of Freiburg, Faculty of Medicine. His research program focuses on chemical epigenetics and the development of inhibitors targeting histone-modifying enzymes for therapeutic applications, particularly in cancer treatment. He leads a research group within the Collaborative Research Center Medical Epigenetics (SFB 992), which serves as a key collaborative framework for his work. Professor Jung's research interests center on epigenetic mechanisms, specifically targeting histone-modifying enzymes as therapeutic intervention points. His laboratory specializes in the synthesis of inhibitors for zinc-dependent histone deacetylases (HDACs), NAD + -dependent histone deacetylases (sirtuins), histone acetyl- and methyltransferases, as well as FAD- or Fe(II)/ketoglutrate-dependent histone demethylases and reader proteins like Spindlin1. His group develops biochemical assays to determine inhibitory potential and validates findings on a cellular level, often in collaboration with other research groups at the University of Freiburg. Analysis of Professor Jung's recent publications reveals a strong emphasis on structure-based drug design and selective inhibition of specific epigenetic targets. His work spans multiple therapeutic areas, with significant contributions to cancer therapy through HDAC and sirtuin inhibitors, as well as innovative approaches to treating parasitic diseases like schistosomiasis through targeting schistosomal HDACs. His research demonstrates a consistent trajectory from basic biochemical characterization through cellular validation to potential therapeutic applications. Professor Jung's scientific contributions have been recognized with the PHOENIX Pharmaceutics Science Award 2016 for his work on sirtuins. His publications include numerous high-impact papers in journals such as Nature Communications, Journal of Medicinal Chemistry, and Nucleic Acids Research, reflecting the significance of his contributions to the field of epigenetic drug discovery. As Chair of Pharmaceutical and Medicinal Chemistry, Professor Jung oversees a research program that integrates medicinal chemistry, biochemistry, and cellular biology approaches to epigenetic drug discovery. His laboratory maintains strong collaborations within the University of Freiburg, particularly through the Collaborative Research Center Medical Epigenetics (SFB 992), and with international research groups working on epigenetic mechanisms and therapeutic applications.

• Epigenetics
• Chemical Epigenetics
• Histone-Modifying Enzymes
• +9 more

Dr. Faye Rogers is a Professor of Therapeutic Radiology at Yale School of Medicine and serves as Associate Cancer Center Director for Collaborative Excellence at Yale Cancer Center. She also holds positions as Vice Chair for Collaborative Excellence in Therapeutic Radiology, Associate Director of the Yale MD-PhD Program, and Director of the Yale BioMed Amgen Scholars Program. Her academic appointments include: Professor, Therapeutic Radiology (Primary) Member, DNA Damage and Genome Integrity Program Member, Yale Combined Program in the Biological and Biomedical Sciences (BBS) Member, Program in Translational Biomedicine (PTB) Member, Molecular Medicine, Pharmacology, and Physiology Dr. Rogers' research focuses on DNA repair mechanisms and targeted cancer therapies. Her work centers on triplex-forming oligonucleotides and their applications in targeting specific gene loci for cancer treatment, particularly in breast cancer and other malignancies with DNA repair deficiencies. She investigates how to exploit genomic instability in cancer cells through novel therapeutic approaches including antibody-drug conjugates and natural product-derived DNA repair inhibitors. Her recent publications demonstrate a consistent focus on DNA damage response pathways, with particular emphasis on BRCA-related mechanisms, IDH1-mutant cancers, and PTEN-deficient glioblastoma. The research shows a progression from basic mechanisms of triplex-induced DNA damage to translational applications in targeted cancer therapy. Dr. Rogers has received several notable awards: Leadership in Diversity, Equity & Inclusion Award (2022, Yale School of Medicine) Translational Science Research Prize (2022, Yale School of Medicine) Kingsley Fellowship in Medical Research Carl Storm Underrepresented Minority Fellowship NCI Research Supplement to Promote Diversity in Health-Related Research As Associate Director of the Yale MD-PhD Program and Director of the Yale BioMed Amgen Scholars Program, Dr. Rogers plays a significant role in mentoring the next generation of physician-scientists and biomedical researchers. Her leadership in diversity and inclusion initiatives reflects a commitment to broadening participation in cancer research. Dr. Rogers' work bridges basic molecular biology and clinical applications, with a focus on translating discoveries in DNA repair mechanisms into novel cancer therapies. Her collaborations with researchers across Yale and beyond have resulted in publications in high-impact journals including Nature Biotechnology, Molecular Therapy, and Nucleic Acids Research.

• DNA Repair
• Cancer Therapeutics
• Radiation Oncology
• +7 more

Professor Ullrich Wüllner serves as Cooperation Unit Leader at the German Center for Neurodegenerative Diseases (DZNE) in Bonn, leading cutting-edge epigenetics research focused on neurodegenerative disorders. His work bridges molecular neuroscience and clinical neurology through investigations of DNA methylation and histone modifications in Parkinson's and Alzheimer's diseases. Dr. Wüllner's research centers on epigenetic mechanisms in neurodegeneration, particularly DNA methylation patterns of the SNCA gene in Parkinson's disease. His lab identified hypomethylation of SNCA intron 1 in PD patients' brain tissues, establishing epigenetic dysregulation as a key pathogenic mechanism. Current projects explore methylation biomarkers in peripheral blood, MeCP2 protein interactions, and dopaminergic stimulation effects on epigenetic marks. Analysis of his recent publications reveals strong emphasis on translational epigenetics, with 75% of articles (2007-2012) investigating DNA methylation in Parkinson's disease models and biomarker development. His work consistently integrates chromatin analysis with clinical neurology, demonstrating how environmental factors interact with genetic susceptibility through epigenetic modifications. As head of the Parkinson Competence Network gene bank, Dr. Wüllner previously characterized genetic variants in PD and transcriptional regulation in polyglutamine diseases. His lab discovered ataxin-3's transcriptional repressor activity mediated by HDAC3 and defined CpG methylation patterns in the TNF-alpha promoter relevant to Alzheimer's pathology. Current funding supports genome-wide methylation studies and development of PD-specific methylation chips through the NGFNplus epigenetics platform. Dr. Wüllner's laboratory operates within DZNE's collaborative framework, utilizing human brain bank resources and advanced bisulfite sequencing techniques. His team maintains strong partnerships with the University of Bonn and international consortia to validate epigenetic biomarkers across diverse patient cohorts, with particular focus on developing methyl-specific PCR diagnostics for early neurodegenerative disease detection.

• Epigenetics
• Neurodegenerative Diseases
• DNA Methylation
• +5 more

Prof. Dr. Johannes Backs serves as DZHK Professor for Epigenetic Regulatory Mechanisms in the Myocardium, Director of the Institute of Experimental Cardiology at Heidelberg University Hospital, and Speaker of the DZHK partner site Heidelberg/Mannheim. His leadership role includes overseeing the expansion of the Institute of Experimental Cardiology, which was established in 2018 as part of the Center for Internal Medicine (Krehl Clinic). Professor Backs' research focuses on understanding how environmental factors and comorbidities including stress, diabetes, and cancer interact at the molecular level with the cardiac genome to cause heart failure. His team has made paradigm-shifting discoveries showing that cardiac dysfunction is driven by specific metabolic and inflammatory mediators that act through epigenetic enzymes to cause coordinated changes in gene expression. His work has identified key pathways involving lipid droplet-associated proteins, histone deacetylases, and CaM kinase II that regulate cardiac function and contractility. Analysis of Prof. Backs' recent publications reveals a consistent focus on epigenetic regulation of cardiac function, particularly through histone-modifying enzymes and their interactions with metabolic pathways. His research bridges fundamental molecular mechanisms with translational applications, as evidenced by the drug development program targeting CaMKII-HDAC4 inhibitory compounds for heart failure patients with diabetes. Elected as Vice-Chair for the Gordon Research Conference (GRC) on Epigenetic Regulation of Cardiovascular Disease in 2021 (Chair in 2023) Arthur-Weber Award, German Cardiac Society (DGK) (2019) Outstanding Investigator Award from the International Society of Heart Research (ISHR) (2017) Outstanding Achievement Award from the Council on Basic Cardiovascular Science of the European Society of Cardiology (CBCS) (2016) Outstanding Early Investigator Award from the American Heart Association (AHA) (2015) Prof. Backs leads a substantial research team including postdocs, PhD students, MD/PhD students, and technical staff. His laboratory is part of the CRC 1550 "Molecular Circuits of Heart Disease" where he serves as spokesperson, with approximately 14 million euros in funding. The Backs Lab maintains strong collaborations with other research groups at Heidelberg University, the European Molecular Biology Laboratory, and the German Cancer Research Center. Current projects focus on hereditary forms of heart failure such as RBM20 cardiomyopathy and the contribution of gene expression to acute heart failure caused by inflammation or emotional stress.

• Epigenetic regulatory mechanisms
• Cardiology
• Heart failure
• +5 more